Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 3/2019

01-03-2019 | Editorial

Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth

Authors: Clara E. Dismuke-Greer, Wing-Kin Syn

Published in: Digestive Diseases and Sciences | Issue 3/2019

Login to get access

Excerpt

Nonalcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in the USA and in other developed nations, is associated with metabolic risk factors including obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, and “non-classical” risk factors such as obstructive sleep apnea and gout [1]. In the USA, the true prevalence of NAFLD is 25–40%, depending on the modalities used to diagnosis NAFLD, and is in parallel with the rising tide of obesity and T2DM [2, 3]. As cardiovascular disease and extrahepatic cancers are the most common causes of death among those with NAFLD [4, 5], NAFLD is now considered a multi-systemic metabolic disease. …
Literature
1.
Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006;54:229–239.PubMed
2.
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed
3.
4.
Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–1197.CrossRefPubMed
5.
Adams LA, Anstee QM, Tilg H, et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–1153.CrossRefPubMed
6.
Younossi Z, Stepanova M, Ong JP et al. Global nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2018. https://​doi.​org/​10.​1016/​j.​cgh.​2018.​0.
7.
Ertle J, Dechêne A, Sowa JP, et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–2443.CrossRefPubMed
8.
Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–817.CrossRefPubMed
9.
Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed
10.
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.e1.CrossRefPubMed
11.
Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.e1.CrossRefPubMed
12.
13.
Herzer K, Hofmann TG, Teufel A, et al. IFNalpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69:855–862.CrossRefPubMed
14.
15.
Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–496.CrossRefPubMed
16.
Huang K-W, Leu H-B, Wang Y-J, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15:830–835.CrossRefPubMed
17.
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.CrossRef
18.
Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.CrossRefPubMedPubMedCentral
19.
Lee D-H, Jacobs DR, Gross M, et al. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51:1185–1191.CrossRefPubMed
20.
Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–1570.CrossRefPubMedPubMedCentral
21.
Sung K-C, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98:3637–3643.CrossRefPubMed
22.
Cartmell KB, Dismuke CE, Dooley M, et al. Effect of an evidence-based inpatient tobacco dependence treatment service on 1-year postdischarge health care costs. Med Care. 2018;56:883–889.CrossRefPubMedPubMedCentral
23.
Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–260.PubMed
24.
Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.CrossRefPubMed
25.
26.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed
Metadata
Title
Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth
Authors
Clara E. Dismuke-Greer
Wing-Kin Syn
Publication date
01-03-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5426-4

Other articles of this Issue 3/2019

Digestive Diseases and Sciences 3/2019 Go to the issue

Original Article

Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold

Original Article

Ineffective Esophageal Motility Is Associated with Impaired Bolus Clearance but Does Not Correlate with Severity of Dysphagia

Original Article

Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice

Fellows and Young GIs Section

Adherence to Two Large-Bore Intravenous Lines in Acute Gastrointestinal Bleeding Is Low

Original Article

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting

Mentored Reviews

Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits